Precise gene expression profiling in your qualified local laboratory
Setting the standard for reliable, reproducible results
Prosigna is powered by nCounter digital technology1
- Strong analytical performance: sensitive, precise, and quantitative
- Single-tube multiplexing: all 50 Prosigna genes are measured in a single reaction—no amplification required
- Easy to use: fully automated, intuitive user interface
References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.
The only breast cancer genomic assay FDA cleared for FFPE tissue
Convenience without compromise
Reference: Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013.
Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or IIIA) early-stage breast cancer to be treated with adjuvant endocrine therapy.
© 2014-2017 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.